ArticleFrontiers in oncology2020
Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- A Critical Examination of the Changes Proposed by the AJCCCCEP for the AJCC 9th Edition Colorectal Cancer Staging System.The American journal of surgical pathology · 2026Article
- T4bN0 colon cancer shows worse survival than T1-2N1 disease: a multicenter real-world study in China.Translational cancer research · 2026Article
- Development of a prognostic risk model for colorectal cancer based on microsatellite stability-associated genes.BMC cancer · 2025Article
- Development and validation of predictive models for disease-free survival and overall survival in non-metastatic right-sided colon adenocarcinoma patients based on inflammatory and nutritional indices.BMC gastroenterology · 2025Article
- Staging Paradox and recurrence pattern among stage IIB, IIC, and IIIA Colon cancers: a retrospective cohort study.International journal of colorectal disease · 2024Article
- Revisiting the survival paradox between stage IIB/C and IIIA colon cancer.Scientific reports · 2024Article
- Article
- Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine.Cancers · 2024Review
- Histopathology and levels of proteins in plasma associate with survival after colorectal cancer diagnosis.British journal of cancer · 2023Article
- High Expression of MRE11A Is Associated with Shorter Survival and a Higher Risk of Death in CRC Patients.Genes · 2023Article
- Combining prognostic nutritional index (PNI) and controlling nutritional status (CONUT) score as a valuable prognostic factor for overall survival in patients with stage I-III colorectal cancer.Frontiers in oncology · 2023Article
- Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- Simultaneous analysis of tumor-infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue.Scientific reports · 2022Article
- Machine learning based prognostic model of Chinese medicine affecting the recurrence and metastasis of I-III stage colorectal cancer: A retrospective study in China.Frontiers in oncology · 2022Article
- Machine Learning-Based Prognostic Prediction Models of Non-Metastatic Colon Cancer: Analyses Based on Surveillance, Epidemiology and End Results Database and a Chinese Cohort.Cancer management and research · 2022Article
- Perineural invasion and number of retrieved lymph nodes are prognostic factors for T2N0 colon cancer.Langenbeck's archives of surgery · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe conducted this large population-based study to re-evaluate the survival paradox between stage IIB/C and stage IIIA colon cancer based on the newest staging criteria.
methodsColon cancer patients were recruited from the Surveillance, Epidemiology, and End Results (SEER) database using SEER*Stat software (version 8.3.4) with strict inclusion criteria. We used Chi-square test to compare categorical variables between patients diagnosed with stage IIB/IIC and stage IIIA colon cancer. Survival probabilities were then assessed using the Kaplan-Meier method. Cox proportional hazards models were used to analyze hazard ratios (HRs) and 95% confidence intervals (CIs) of clinicopathologic characteristics in stage IIB/IIC and stage IIIA colon cancer patients.
resultsIn the current study, a total of 9,227 eligible colon cancer patients were collected from the SEER database between 2010 and 2015. It was found that stage IIIA had 66.4% decreased risk of colon cancer-specific mortality compared with stage IIB (HR = 0.336, 95%CI = 0.286-0.394 for stage IIIA, P < 0.001, using stage IIB as the reference) after the adjustment for other known prognostic factors. And T1N2a colon cancer had significantly lower 5-year overall survival (OS) rate compared with T2N1 disease (74.7% vs. 57.1%, P = 0.018).
conclusionsOur study confirmed the existence of survival paradox between stage IIB/IIC and stage IIIA colon cancer based on the newest staging criteria. What is more, the subgroup analyses revealed that T1N2a had the least influence on the survival paradox. N2a colon cancer seemed to be associated with worse prognosis than T2 disease, which would give us a better understanding of tumor biology of colon cancer and be conducive to the refinement of individualized treatment regimens in stage III disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.